Xin Li
Zhejiang Chinese Medical University(CN)Union Hospital(CN)Ministry of Education of the People's Republic of China(CN)Harbin Medical University(CN)Sun Yat-sen University(CN)China Pharmaceutical University(CN)Kunming Medical University(CN)Soochow University(CN)Nanjing Health and Health Commission(CN)Heilongjiang Academy of Sciences(CN)Nanjing Traditional Chinese Medicine Hospital(CN)Hubei Provincial Center for Disease Control and Prevention(CN)Nanjing Drum Tower Hospital(CN)Gannan Medical University(CN)Qingdao National Laboratory for Marine Science and Technology(CN)State Key Laboratory of Information Engineering in Surveying Mapping and Remote Sensing(CN)Zhujiang Hospital(CN)Changchun University of Chinese Medicine(CN)Center for Global Health(US)Second Affiliated Hospital of Nanjing Medical University(CN)Hangzhou Hospital of Traditional Chinese Medicine(CN)Jiangsu Hengrui Medicine (China)(CN)Changzhou No.2 People's Hospital(CN)Changzhou Third People's Hospital(CN)Children's Hospital of Chongqing Medical University(CN)First People's Hospital of Chongqing(CN)Department of Health Services(US)Fourth People's Hospital of Changzhou(CN)Huazhong University of Science and Technology(CN)Ocean University of China(CN)Nanjing Medical University(CN)Chongqing Medical University(CN)Nanjing University(CN)
Publications by Year
Research Areas
Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Economic and Financial Impacts of Cancer, Hepatocellular Carcinoma Treatment and Prognosis, Renal cell carcinoma treatment
Most-Cited Works
- → Laparoscopic versus conventional appendectomy - a meta-analysis of randomized controlled trials(2010)403 cited
- → Targeting the untargetable KRAS in cancer therapy(2019)349 cited
- → Identification of Nore1 as a Potential Ras Effector(1998)206 cited
- → Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer(2021)162 cited
- → Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial—The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy Trial(2001)150 cited
- → KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge(2022)138 cited